Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure Biosciences Inc positioned for success in 2016

Pressure cycling specialist Pressure BioSciences is well positioned for success in 2016 as it outlined a period of significant progress in the year gone.
Pressure Biosciences Inc positioned for success in 2016
The firm develops and sells lab equipment to the estimated $6 billion life sciences sample preparation market

Pressure cycling specialist Pressure BioSciences (OTCMKTS:PBIO) is well positioned for success in 2016 as it outlined a period of significant progress in the year gone.

The firm develops and sells lab equipment to the estimated $6 billion life sciences sample preparation market.

And its proprietary PCT-HD system - a new technique for ‘opening’ cells using pulses of pressure - has in recent years been adopted by leading scientists.

So far, it has installed over 250 PCT systems in around 160 sites worldwide.

Increased research and development costs and admin  expenses pushed the operating loss up to $3.5mln for the year to end December, compared to a loss of $3.3mln in 2014, but total revenue was lifted to around $1.8mln compared to $1.37mln in 2014.

Grant revenue was significantly increased to $387,700 compared to $24,594 in 2014, an increase of around 1,500% due to the receipt of a SBIR Phase II grant.

The group's president and chief Richard T. Schumacher told investors: "We accomplished a number of key goals in 2015: the receipt of approximately $5M in new capital; the elimination of all toxic debt; the release of new pressure-based instruments and consumables; the initial development of the new Barocycler NEP2320 Extreme – designed to allow SCIEX and other mass spectrometry customers to unleash the full potential of PCT in their proteomic workflows; and the initiation of a co-marketing agreement with SCIEX, a key provider of analytical instrumentation to the scientific research markets worldwide."

The company boss went onto say: "These accomplishments, combined with the planned expansion of our marketing and sales capabilities this year, position us well for success in 2016 and beyond.

"We have well-defined near-term goals that we believe are clear, focused, and attainable. If achieved, we believe these goals should continue to build value realization in PBI, positioning us as a stronger, more valuable company going forward."

Among its short term goals this year are to complete the manufacture of the Barocycler NEP2320 Extreme and begin its commercialisation and expand its co-marketing program with SCIEX.

It also wants to secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use